Jul 27, 2021 / 12:00PM GMT
Operator
Good morning, and welcome to the Infinity Pharmaceuticals KOL event on the MARIO-275 UC study update and the MARIO-3 TNBC study update. (Operator Instructions) As a reminder, today's event is being recorded, and a replay will be made available on the Infinity Pharmaceuticals website following the conclusion of today's event.
I would now like to turn the call over to your host, Jayne Kauffman, Senior Administrative Manager at Infinity. Please go ahead, Jayne.
Jayne Kauffman - Infinity Pharmaceuticals, Inc. - Senior Executive Coordinator
Good morning, everyone, and welcome to today's call, where we will review data updates from MARIO-275 in second-line urothelial cancer and MARIO-3 in first-line triple-negative breast cancer. Participants on today's call are Adelene Perkins, Chief Executive Officer; and Dr. Brian Schwartz, Consulting Chief Physician from Infinity Pharmaceuticals; and Dr. Erika Hamilton, Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncolgy and MARIO-3 lead study
Infinity Pharmaceuticals Inc KOL Webinar to Discuss MARIO-3 and MARIO-275 Phase 2 Trials Transcript
Jul 27, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers